J-Star Signs Exclusive Distribution Agreement with PSSB
TAICHUNG CITY, Taiwan, Feb. 23, 2026 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions serving diverse applications including personal sports equipment, healthcare products, automobile parts, resin systems, and research and development services, today announced that it has entered into an exclusive global distribution agreement with Patriot Green Energy Technology (“PSSB”).
PSSB is a leading industry developer and manufacturer of next-generation solid state battery technology for high-performance and defense applications with a large minority ownership by Industrial Technology Research Institute (“ITRI”), one of Taiwan’s most prominent applied research institutions and a globally recognized technology incubator that is recognized as a trusted partner in the US, as demonstrated by the recent signing with the Association for Uncrewed Vehicle Systems International (“AUVSI”) as a “Recognized Cybersecurity Assessor” for the Green USA Program.
Through this agreement, J-Star will serve as the sole exclusive global distributor of PSSB’s products in the areas of “Electric Assist Bicycles and Electric Motorcycles” as well as non-exclusive distributions rights in other PSSB’s products.
“We are proud to extend our partnership with PSSB and to formalize our exclusive distribution relationship after signing our MOU earlier this year,” said Jonathan Chiang, Chairman of J-Star. “PSSB is the gold standard in solid state battery development and our partnership provides J-Star with this unique positioning to leverage the world-class R&D heritage of Taiwan’s ITRI. We believe this agreement significantly strengthens J-Star’s role in the energy storage ecosystem application for sports equipment and enhances our product offerings.”
About J-Star Holding Co., Ltd.
J-Star (NASDAQ: YMAT) is a holding company with operations conducted through subsidiaries in Taiwan, Hong Kong, and Samoa with its headquarters in Taiwan. J-Star’s predecessor group was established in 1970, and has accumulated over 50 years of know-how in material composites industry. J-Star develops and commercializes the technology on carbon reinforcement and resin systems. With decades of experience and knowledge in composites and materials, J-Star is able to apply its expertise and technology to design and manufacture a great variety of lightweight, high-performance carbon composite products, ranging from key structural parts of electric bicycles and sports bicycles, rackets, automobile parts to healthcare products. Visit j-starholding.com and ymacorp.com to learn more.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"
Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
Crypto prices
More
